Tsuzuki, Hirofumi Kawase, Tatsuya Nakazawa, Taisuke Mori, Masamichi Yoshida, Taku
Published in
Oncotarget
Antibody drug conjugates (ADC) are one of the attractive modalities for the treatment of acute myeloid leukemia (AML). Previously, we have developed ASP1235, a novel ADC targeting Fms-like tyrosine kinase 3 (FLT3) which is widely expressed on the leukemic blasts of AML patients. In this study, we sought to evaluate the therapeutic effect of ASP1235...
Yuan, Hongyan Jin, Lu Xiang, Handan Bhattacharya, Anannya Brandish, Philip E Baltus, Gretchen Tong, Alexander Zhou, Changyan Glazer, Robert I
Published in
Oncotarget
One of the central challenges for cancer therapy is the identification of factors in the tumor microenvironment that increase tumor progression and immune tolerance. In breast cancer, fibrosis is a histopathologic criterion for invasive cancer and poor survival that results from inflammatory factors and remodeling of the extracellular matrix to pro...
Liu, Xue Song, Xiuhui Lu, Jianjun Chen, Xueying Liang, Ershun Liu, Xiaoqiong Zhang, Mingxiang Zhang, Yun Du, Zhanhui Zhao, Yuxia
...
Published in
Oncotarget
Bernabé-Caro, Reyes Garrido, Pilar García-Campelo, Rosario Palmero, Ramón Artal, Ángel Bayona, Cristina Rodríguez-Abreu, Delvys López-Brea, Marta Paredes, Alfredo Vicente, David
...
Published in
Oncotarget
This retrospective observational study analyzed the clinical characteristics, treatment patterns and outcomes of 120 patients with advanced ALK-positive non-small-cell lung cancer (ALK+ NSCLC) according to data collected between November 2019 and October 2020 in 38 Spanish hospitals. Patients had progressed after 1–5 prior treatment lines (which in...
Ulanja, Mark B. Moody, Alastair E. Beutler, Bryce D. Antwi-Amoabeng, Daniel Rahman, Ganiyu A. Alese, Olatunji B.
Published in
Oncotarget
Objectives: Early-onset pancreatic cancer (EOPC) – defined as pancreatic cancer diagnosed before the age of 50 years – is associated with a poor prognosis as compared to later-onset pancreatic cancer (LOPC). Emerging evidence suggests that EOPC may exhibit a genetic signature and tumor biology that is distinct from that of LOPC. We review genetic m...
Yang, Chao Tan, Juan Zhu, Jun Wang, Shan Wei, Guanghui
Published in
Oncotarget
[This corrects the article DOI: 10.18632/oncotarget.16209.]. Copyright: © 2022 Yang et al.
Tran, Chau P Scurr, Michelle O'Connor, Louise Buzzelli, Jon N Ng, Garrett Z Chin, Sharleen Chung Nien Stamp, Lincon A Minamoto, Toshinari Giraud, Andrew S Judd, Louise M
...
Published in
Oncotarget
Interleukin-33 (IL-33) is an IL-1 family cytokine known to promote T-helper (Th) type 2 immune responses that are often deregulated in gastric cancer (GC). IL-33 is overexpressed in human gastric tumours suggesting a role in driving GC progression although a causal link has not been proven. Here, we investigated the impact of IL-33 genetic deficien...
Hiddinga, Birgitta Zwaenepoel, Karen Janssens, Annelies Van Meerbeeck, Jan Pauwels, Patrick
Published in
Oncotarget
Novel targets in neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are needed to improve outcome. The presence of O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation in NETs and NECs may act as a predictive marker for response on treatment with temozolomide. As anaplastic lymphoma kinase (ALK) plays an important role ...
Guerriero, Ilaria D’Angelo, Daniela Pallante, Pierlorenzo Santos, Mafalda Scrima, Marianna Malanga, Donatella De Marco, Carmela Ravo, Maria Weisz, Alessandro Laudanna, Carmelo
...
Published in
Oncotarget
Chaudhry, Saliha Thomas, Stefani N. Simmons Jr., Glenn E.
Published in
Oncotarget
Cancer cells undergo alterations in lipid metabolism to support their high energy needs, tumorigenesis and evade an anti-tumor immune response. Alterations in fatty acid production are controlled by multiple enzymes, chiefly Acetyl CoA Carboxylase, ATP-Citrate Lyase, Fatty Acid Synthase, and Stearoyl CoA Desaturase 1. Ovarian cancer (OC) is a commo...
